Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Lucas Research Admin

Neither a doctor nor a teaching hospital

Research payments

$2,339,161

312 payments

Through program year 2025, Lucas Research Admin is reported as receiving $2,339,161 in research payments, across 312 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $817,911 301
2024 Research $1,521,250 11

Breakdown

Who paid Research payments · program years 2024–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $2,187,598 90 payments
  2. Boehringer Ingelheim International GmbH $144,885 221 payments
  3. Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
Studies the money was for Research payments · program years 2024–2025
  1. Phase III efficacy for obesity - without T2DM $735,762 3 payments
  2. phase III efficacy for obesity - with T2DM $459,256 3 payments
  3. Obesity Long term safety in patients with CV risk $283,102 1 payment
  4. A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes $272,202 106 payments
  5. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $216,592 16 payments
  6. A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus $186,313 82 payments
  7. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $78,538 57 payments
  8. A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD $39,052 21 payments
  9. A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $23,393 10 payments
  10. POCC in NASH $21,212 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record